Cipher To Discuss Filing Strategy For CIP-Isotretinoin With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency refuses to file Cipher's 505(b)(2) NDA for the acne drug because it believes the submission is eligible for filing as an ANDA, the company says.